Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.55 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.48 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548347 | 1.00 | NAAA (0.55) | NAAACNR1POLBTHRBRECQL | |
| SCHEMBL15887754 | 1.00 | NAAA (0.55) | NAAACNR1POLBTHRBRECQL | |
| SCHEMBL6714042 | 0.85 | AKR1C4 (0.58) | POLBTHRBRECQLTDP1L3MBTL1 | |
| SCHEMBL5656756 | 0.84 | FABP4 (0.55) | POLBALDH1A1LMNASMN1; SMN2CA12 | |
| SCHEMBL5656226 | 0.84 | FABP4 (0.55) | POLBALDH1A1LMNASMN1; SMN2CA12 | |
| SCHEMBL5656980 | 0.84 | FABP4 (0.55) | POLBALDH1A1LMNASMN1; SMN2CA12 | |
| SCHEMBL4614744 | 0.84 | FABP4 (0.55) | POLBALDH1A1LMNASMN1; SMN2CA12 | |
| SCHEMBL13545500 | 0.84 | FABP4 (0.55) | POLBALDH1A1LMNASMN1; SMN2CA12 | |
| SCHEMBL5656630 | 0.84 | FABP4 (0.55) | POLBALDH1A1LMNASMN1; SMN2CA12 | |
| SCHEMBL2454782 | 0.82 | AKR1C4 (0.55) | POLBTHRBRECQLTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458174-B2 | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof | STEMERGIE BIOTECHNOLOGY SA (CH) | 2016-10-04 | — | — | US | claimed |
| US-20150148301-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA a corporation | 2015-05-28 | — | — | US | claimed |
| EP-2852439-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA (CH) | 2015-04-01 | — | — | EP | claimed |
| WO-2013174947-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | STEMERGIE BIOTECHNOLOGY SA (CH) | 2013-11-28 | — | — | WO | claimed |
| CN-109689051-B | Use of inhibitors of mitochondrial activity for the treatment of acute myeloid leukemia with poor prognosis | 蒙特利尔大学 | 2022-03-29 | — | — | CN | disclosed |
| US-20200188361-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | UNIVERSITE DE MONTREAL (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20190192488-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | Université de Montréal (CA) | 2019-06-27 | — | — | US | disclosed |
| US-9458174-B2 | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof | STEMERGIE BIOTECHNOLOGY SA (CH) | 2016-10-04 | — | — | US | disclosed |
| US-9458174-B2 | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof | STEMERGIE BIOTECHNOLOGY SA (CH) | 2016-10-04 | — | — | US | disclosed |
| US-20150148301-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA a corporation | 2015-05-28 | — | — | US | disclosed |
| US-20150148301-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA a corporation | 2015-05-28 | — | — | US | disclosed |
| EP-2852439-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA (CH) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013174947-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | STEMERGIE BIOTECHNOLOGY SA (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174947-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | STEMERGIE BIOTECHNOLOGY SA (CH) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188361-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | NPM1, TFAM, NDUFAF1 | NAAA 3760/4885CNR1 4653/4885POLB 315/4885 |
| US-20150148301-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | NDUFB3, MT-CO3, SLC25A1 | NAAA 1871/4885CNR1 4236/4885POLB 273/4885 |
| US-20190192488-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | IDH2, TFAM, NUTF2 | NAAA 3262/4885CNR1 4586/4885POLB 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.